Jasper Therapeutics
JSPR | NASDAQ
$11.77
-$1.91 (-13.96%)
At close: Nov 16, 2026, 4:00 PM ET
$12.41
+$0.64 (+5.44%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Jasper Therapeutics Company Profile
Company profile explainedCompany Profile
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company’s lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. was founded in 2018 and is based in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| Jeetinder Singh Mahal | President, CEO, Interim CFO & Director |
| Herbert C. Cross | Chief Financial Officer & Corporate Secretary |
| Alex Gray | Head of Investor Relations |
| Gregory F. Keenan | Chief Medical Officer |
| Judith Anne Shizuru | Co-Founder, Member of Scientific Advisory Board & Director |
| Lisa Pitt | Senior Vice President of Regulatory Affairs |
| Matthew E. Ros | COO & Interim Corporate Secretary |
| Matthew Ford | Senior Vice President of Human Resources |
| Thomas G. Wiggans | Executive Chairman |
| Wenru Song | Executive VP and Head of R&D |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 09, 2026 | 8-K | Current Report |
| Nov 04, 2026 | 8-K | Current Report |
| Oct 28, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 23, 2026 | SC TO-I/A | [Amend] Filing |
| Oct 19, 2026 | DEF 14A | Filing |
| Oct 15, 2026 | 8-K | Current Report |
| Oct 14, 2026 | S-3 | Filing |
| Oct 09, 2026 | PRE 14A | Filing |
| Oct 07, 2026 | 8-K | Current Report |
| Oct 07, 2026 | SC TO-I | Filing |
Jasper Therapeutics
| Country | United States |
| IPO Date | Jan 10, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 22 |
| CEO | Jeetinder Singh Mahal |
Contact Details
2200 Bridge Pkwy Redwood City,
California 94065 United States
Stock Details
| Ticker Symbol | JSPR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001788028 |
| CUSIP Number | 471871301 |
| ISIN Number | US4718713013 |
| SIC Code | 2836 |
Recent News
- 8 days ago / globenewswire.comJasper Therapeutics, Inc. Announces Results of the Offer to Purchase Relating to Its Warrants
- 13 days ago / globenewswire.comJasper Therapeutics Announces 1-for-30 Reverse Stock Split
- 1 month ago / globenewswire.comJasper Therapeutics Announces Completion of Enrollment in First Cohort of Phase 2 Renal Basket Study Evaluating Vensobafusp Alfa (KP104) in IgA Nephropathy
- 1 month ago / globenewswire.comJasper Therapeutics Announces Commencement of an Offer to Purchase Outstanding Warrants
- 2 months ago / globenewswire.comJasper Therapeutics Announces Key Regulatory and Clinical Appointments
- 2 months ago / globenewswire.comJasper Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
- 3 months ago / globenewswire.comJasper Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Add to Watchlist
Select watchlists to add or remove JSPR